Inhibition of poly(ADP-ribose) polymerase (PARP) and ataxia telangiectasia mutated (ATM) on the chemosensitivity of mantle cell lymphoma to agents that induce DNA strand breaks

Hematological Oncology

Volumn 30, Issue 4, 2012, Pages 175-179

  Golla, Radha M ^a   Li, Min ^a   Shen, Yulei ^a   Ji, Ming ^a   Yan, Ying ^b   Fu, Kai ^a   Greiner, Timothy C ^a   Mckeithan, Timothy W ^a   Chan, Wing C ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

ATM; Mantle cell lymphoma; PARP inhibitor

Indexed keywords

AG 14361; BRCA2 PROTEIN; CHECKPOINT KINASE 2; ENZYME INHIBITOR; POLY(ADENOSINE DIPHOSPHATE RIBOSE); PROTEIN P53; SINGLE STRANDED DNA; TOPOTECAN; UNCLASSIFIED DRUG;

ARTICLE; ATAXIA TELANGIECTASIA; CANCER CELL CULTURE; CHEMOSENSITIVITY; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MANTLE CELL LYMPHOMA; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

BRCA2 PROTEIN; CELL CYCLE PROTEINS; DNA BREAKS, SINGLE-STRANDED; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GAMMA RAYS; HUMANS; LYMPHOMA, MANTLE-CELL; PHOSPHORYLATION; POLY(ADP-RIBOSE) POLYMERASES; PROTEIN-SERINE-THREONINE KINASES; RNA, SMALL INTERFERING; TOPOISOMERASE I INHIBITORS; TOPOTECAN; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84870921108     PISSN: 02780232     EISSN: 10991069     Source Type: Journal    
DOI: 10.1002/hon.1020     Document Type: Article

References (39)

1. A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89(11): 3909-3918. Epub 1997/06/01.
2. Gill S, Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma 2008; 49(3): 398-409. Epub 2008/02/26.
3. Bosch F, Jares P, Campo E, et al. PRAD-1/cyclin D1 gene overexpression in chronic lymphoproliferative disorders: a highly specific marker of mantle cell lymphoma. Blood 1994; 84(8): 2726-2732. Epub 1994/10/15.
4. Jares P, Colomer D, Campo E. Genetic and molecular pathogenesis of mantle cell lymphoma: perspectives for new targeted therapeutics. Nat Rev Cancer 2007; 7(10): 750-762. Epub 2007/09/25.
5. Vater I, Wagner F, Kreuz M, et al. GeneChip analyses point to novel pathogenetic mechanisms in mantle cell lymphoma. Br J Haematol 2009; 144(3): 317-331. Epub 2008/11/20.
6. Kurz EU, Lees-Miller SP. DNA damage-induced activation of ATM and ATM-dependent signaling pathways. DNA Repair 2004; 3(8-9): 889-900. Epub 2004/07/29.
7. Uziel T, Lerenthal Y, Moyal L, Andegeko Y, Mittelman L, Shiloh Y. Requirement of the MRN complex for ATM activation by DNA damage. EMBO J 2003; 22(20): 5612-5621. Epub 2003/10/09.
8. Williams RS, Williams JS, Tainer JA. Mre11-Rad50-Nbs1 is a keystone complex connecting DNA repair machinery, double-strand break signaling, and the chromatin template. Biochem Cell Biol 2007; 85(4): 509-520. Epub 2007/08/24.
9. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421(6922): 499-506. Epub 2003/01/31.
10. Lavin MF, Kozlov S. ATM activation and DNA damage response. Cell Cycle 2007; 6(8): 931-942. Epub 2007/04/26.
11. Matsuoka S, Ballif BA, Smogorzewska A, et al. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science 2007; 316(5828): 1160-1166. Epub 2007/05/26.
12. Rotman G, Shiloh Y. ATM: a mediator of multiple responses to genotoxic stress. Oncogene 1999; 18(45): 6135-6144. Epub 1999/11/11.
13. Lieber MR. The mechanism of human nonhomologous DNA end joining. J Biol Chem 2008; 283(1): 1-5. Epub 2007/11/15.
14. Brown EJ, Baltimore D. ATR disruption leads to chromosomal fragmentation and early embryonic lethality. Genes Dev 2000; 14(4): 397-402. Epub 2000/02/26.
15. de Klein A, Muijtjens M, van Os R, et al. Targeted disruption of the cell-cycle checkpoint gene ATR leads to early embryonic lethality in mice. Curr Biol 2000; 10(8): 479-482. Epub 2000/05/10.
16. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science 2001; 294(5547): 1713-1716. Epub 2001/11/27.
17. Brown EJ, Baltimore D. Essential and dispensable roles of ATR in cell cycle arrest and genome maintenance. Genes Dev 2003; 17(5): 615-628. Epub 2003/03/12.
18. Cimprich KA, Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol 2008; 9(8): 616-627. Epub 2008/07/03.
19. Paulsen RD, Cimprich KA. The ATR pathway: fine-tuning the fork. DNA Repair 2007; 6(7): 953-966. Epub 2007/05/29.
20. D'Amours D, Desnoyers S, D'Silva I, Poirier GG. Poly(ADP-ribosyl)ation reactions in the regulation of nuclear functions. Biochem J 1999; 342(Pt 2): 249-268. Epub 1999/08/24.
21. Nagaraju G, Scully R. Minding the gap: the underground functions of BRCA1 and BRCA2 at stalled replication forks. DNA Repair 2007; 6(7): 1018-1031. Epub 2007/03/24.
22. Boulton SJ. Cellular functions of the BRCA tumour-suppressor proteins. Biochem Soc Trans 2006; 34(Pt 5): 633-645. Epub 2006/10/21.
23. Bryant HE, Schultz N, Thomas HD, et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 2005; 434(7035): 913-917. Epub 2005/04/15.
24. Farmer H, McCabe N, Lord CJ, et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 2005; 434(7035): 917-921. Epub 2005/04/15.
25. Bryant HE, Helleday T. Inhibition of poly (ADP-ribose) polymerase activates ATM which is required for subsequent homologous recombination repair. Nucleic Acids Res 2006; 34(6): 1685-1691. Epub 2006/03/25.
26. Calabrese CR, Almassy R, Barton S, et al. Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 2004; 96(1): 56-67. Epub 2004/01/08.
27. Hickson I, Zhao Y, Richardson CJ, et al. Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM. Cancer Res 2004; 64(24): 9152-9159. Epub 2004/12/18.
28. Smith LM, Willmore E, Austin CA, Curtin NJ. The novel poly(ADP-ribose) polymerase inhibitor, AG14361, sensitizes cells to topoisomerase I poisons by increasing the persistence of DNA strand breaks. Clin Cancer Res 2005; 11(23): 8449-8457. Epub 2005/12/03.
29. Biton S, Dar I, Mittelman L, Pereg Y, Barzilai A, Shiloh Y. Nuclear ataxia-telangiectasia mutated (ATM) mediates the cellular response to DNA double strand breaks in human neuron-like cells. J Biol Chem 2006; 281(25): 17482-17491. Epub 2006/04/22.
30. Paddison PJ, Cleary M, Silva JM, et al. Cloning of short hairpin RNAs for gene knockdown in mammalian cells. Nat Methods 2004; 1(2): 163-167. Epub 2005/09/08.
31. Wigler M, Silverstein S, Lee LS, Pellicer A, Cheng Y, Axel R. Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells. Cell 1977; 11(1): 223-232. Epub 1977/05/01.
32. Tiscornia G, Singer O, Verma IM. Production and purification of lentiviral vectors. Nat Protoc 2006; 1(1): 241-245. Epub 2007/04/05.
33. Lois C, Hong EJ, Pease S, Brown EJ, Baltimore D. Germline transmission and tissue-specific expression of transgenes delivered by lentiviral vectors. Science 2002; 295(5556): 868-872. Epub 2002/01/12.
34. Camps J, Salaverria I, Garcia MJ, et al. Genomic imbalances and patterns of karyotypic variability in mantle-cell lymphoma cell lines. Leuk Res 2006; 30(8): 923-934. Epub 2006/02/02.
35. Jeon HJ, Kim CW, Yoshino T, Akagi T. Establishment and characterization of a mantle cell lymphoma cell line. Br J Haematol 1998; 102(5): 1323-1326. Epub 1998/09/30.
36. Salaverria I, Perez-Galan P, Colomer D, Campo E. Mantle cell lymphoma: from pathology and molecular pathogenesis to new therapeutic perspectives. Haematologica 2006; 91(1): 11-16. Epub 2006/01/26.
37. Williamson CT, Muzik H, Turhan AG, et al. ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther 2010; 9(2): 347-357. Epub 2010/02/04.
38. Jiang H, Reinhardt HC, Bartkova J, et al. The combined status of ATM and p53 link tumor development with therapeutic response. Genes Dev 2009; 23(16): 1895-1909. Epub 2009/07/18.
39. Greiner TC, Dasgupta C, Ho VV, et al. Mutation and genomic deletion status of ataxia telangiectasia mutated (ATM) and p53 confer specific gene expression profiles in mantle cell lymphoma. Proc Natl Acad Sci USA 2006; 103(7): 2352-2357. Epub 2006/02/08.